About PipelineEvidence
Our Mission
PipelineEvidence is a comprehensive oncology intelligence platform designed to provide healthcare professionals, clinical researchers, and the broader medical community with accurate, current, and actionable information about FDA and EMA-approved cancer therapies. We believe that centralized, well-organized access to treatment data improves clinical decision-making and ultimately benefits patient care.
Our platform currently covers 50 tumor types with over 218 unique FDA-approved therapies and more than 600 active clinical trials from both US (ClinicalTrials.gov) and European (EudraCT) registries, making it one of the most comprehensive comparative oncology resources available.
Editorial Team & Expertise
PipelineEvidence is developed and maintained by a team with professional backgrounds in clinical oncology, pharmaceutical sciences, and health informatics. Our editorial process is informed by direct experience in oncology clinical practice, clinical trial operations, and drug information analysis.
Every drug profile, editorial section, and clinical trial listing on our platform undergoes a structured review process that includes verification against primary sources (FDA prescribing information, peer-reviewed publications, ClinicalTrials.gov), cross-referencing of clinical data points, and periodic review for accuracy as new information becomes available.
Our detailed editorial methodology is described on our Methodology page, including data sources, verification procedures, and update processes.
What We Provide
Comprehensive Drug Profiles
Each therapy entry includes brand and generic names, drug class and mechanism of action, complete FDA-approved indications, dosing information, approval year, pivotal trial data with direct ClinicalTrials.gov links, and manufacturer information. Entries are organized by molecular targets and treatment lines to reflect clinical decision-making.
Clinical Trial Pipeline
Over 600 active clinical trials across Phase 1, 2, and 3 are documented with NCT/EudraCT numbers, study titles, interventions, primary endpoints, enrollment targets, and direct registry links. This pipeline view provides insight into emerging treatments that may change future standards of care.
Tumor-Specific Editorial Content
Each of our 50 tumor pages includes expert-level editorial sections covering epidemiology and risk factors, molecular biology and biomarkers, the evolving treatment landscape, and frequently asked questions with structured data markup. These sections provide clinical context that transforms raw drug data into actionable intelligence.
SEER Cancer Statistics
For 26 major tumor types, we integrate population-level statistics from the NCI SEER (Surveillance, Epidemiology, and End Results) program and the American Cancer Society, including incidence, mortality, survival by stage, demographic breakdowns, and temporal trends. All SEER data is properly cited per NCI reuse policy.
Data Sources & Standards
PipelineEvidence is built on authoritative data sources:
Drug approvals, prescribing information, label updates
US clinical trial registry (NCT numbers)
European approvals and trial registry
Cancer statistics and epidemiology data
NEJM, Lancet Oncology, JCO, and other journals
Treatment guidelines and standards of care
Important Disclaimer
PipelineEvidence is designed as an informational resource and does not provide medical advice. The information on this platform should not be used as a substitute for consultation with qualified healthcare professionals. Treatment decisions should always be made in partnership with an oncologist who can consider the full clinical context of each patient's situation.
For our complete disclaimers and policies, please review our Medical Disclaimer, Terms of Use, and Privacy Policy.
Contact
We welcome feedback, corrections, and suggestions for improving PipelineEvidence. If you identify an error, have a question about our data, or would like to suggest an addition, please visit our Contact page.